ArticleBMC infectious diseases2026
Prevalence, clinical features and determinants of cutaneous leishmaniasis in central Ethiopia.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCutaneous Leishmaniasis (CL) represents the prevalent form of leishmaniasis affecting the most disadvantaged communities globally. It presents a notable public health concern, particularly in low and middle-income countries like Ethiopia. Numerous research efforts have addressed the problem of CL across Ethiopia, yet the central region, specifically the Kambata Zone, remained understudied. Consequently, this study aimed to investigate the prevalence, clinical features, and determinants of CL infection in the area.
methodsA community-based cross-sectional study was conducted in the Kambata Zone from February 1 to August 30, 2024, including participants of all ages and both sexes. Study participants were randomly selected, and data were collected using a pre-tested structured questionnaire. Clinical samples were obtained from individuals suspected of having cutaneous leishmaniasis (CL) by aspirating ulcers or nodules, and the samples were examined using Giemsa-stained smear microscopy. Data were entered into Epi Info software and analyzed using SPSS version 25.0. Descriptive statistics were used to summarize the data, while bivariate and multivariate logistic regression models were applied to identify factors associated with CL infection. Results are presented as adjusted odds ratios (AOR) with 95% confidence intervals (CI), and statistical significance was set at p < 0.05.
resultsAmong 306 participants, microscopic examination identified 45 cases of CL, yielding a prevalence of 14.7% (45/306) [95% CI: 10.94–18.48%]. Clinically, lesions most commonly affected the nose (26/45, 57.7%), with the majority of cases presenting two lesions (31/45, 68.8%), and 20/45 cases (44.4%) persisting for more than one year. Multivariate logistic regression analysis showed that being male (AOR = 4.32; 95% CI: 2.03–6.82; p < 0.03), age under 18 years (AOR = 3.32; 95% CI: 1.76–5.12; p < 0.02), rural residence (35/45; AOR = 2.64; 95% CI: 1.79–12.55; p < 0.01), a family history of CL (AOR = 4.65; 95% CI: 1.44–10.89; p < 0.01), and the presence of a household garden (AOR = 7.91; 95% CI: 1.25–19.97; p < 0.01) were statistically significant determinants of CL infection.
conclusionThe study revealed a higher prevalence of CL that demonstrates various clinical features in Ethiopia. Notably, the occurrence of the infection is linked with age, sex, rural residence, previous infection, and presence of a garden, implicating the importance of targeted preventive and control measures.
trial registrationNot applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.